NCT07723638Not yet recruiting
New Diagnostic Approaches in the Management of Inflammatory Lung Diseases
Source: ClinicalTrials.gov · Last updated 23 Jul 2026
Brief summary (registry, in English)
Inflammatory lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), are major causes of morbidity and mortality worldwide. Their development and progression are influenced by environmental exposures, such as cigarette smoking and air pollution, as well as genetic susceptibility. Despite advances in disease management, early diagnosis, accurate differential diagnosis, personalized treatment, and continuous monitoring remain significant clinical challenges. This project aims to improve the management of inflammatory lung diseases through the development and validation of innovative diagnostic, monitoring, and therapeutic approaches. The study will identify and validate multi-omics biomarkers for the differential diagnosis and prognosis of COPD, IPF, and related respiratory diseases, using machine learning techniques to develop diagnostic and prognostic biochips. Environmental determinants, including indoor and outdoor exposome factors, will be assessed to better understand their contribution to pulmonary inflammation and disease progression. The project will also develop nanotechnology-based therapeutic formulations combined with precision inhalation devices and integrate a telemedicine platform for real-time monitoring of clinical and environmental data, enabling the early detection of exacerbations and supporting personalized disease management. The expected outcomes include improved diagnostic accuracy, enhanced risk stratification, personalized therapeutic strategies, reduced disease exacerbations, and improved quality of life for patients with inflammatory lung diseases.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 8 Jul 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Fondazione Don Carlo Gnocchi ETS
- Diseases
- Idiopathic pulmonary fibrosis, COPD
- NCT number
- NCT07723638
What you commit to
- Study type: Interventional
- Planned participants: 200
- From 1 Sept 2026 to the primary completion date, 30 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of any medical, psychiatric, or cognitive condition that, in the opinion of the investigator, would interfere with study participation or interpretation of the study results.
Age
- Age younger than 18 years.
Other
- Inability or unwillingness to provide written informed consent.
- Inability to comply with study procedures or scheduled follow-up.
- Participation in another interventional clinical trial that, in the opinion of the investigator, could interfere with the objectives of this study.
Who the study is looking for
- Adults aged 18 years or older.
- Diagnosis of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or combined pulmonary fibrosis and emphysema (CPFE), established according to current international diagnostic guidelines.
- Ability and willingness to provide written informed consent.
- Willingness to provide blood and saliva samples for biomarker analyses.
- Willingness and ability to undergo clinical assessments and scheduled follow-up visits.
- Willingness and ability to use study monitoring devices, including environmental monitoring devices and, where applicable, telemedicine tools.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.